Seikagaku and Eisai entered into an agreement to co-develop and co-market the SI-613 therapeutic agent to treat knee osteoarthritis in South Korea. This follows a similar agreement between the companies, signed earlier this year, addressing the market in China.
Eisai Korea will acquire exclusive marketing rights for SI-613 in South Korea and apply for manufacturing and marketing approval. Following approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution. Eisai will pay Seikagaku the upfront payment and sales milestones.
SI-613 uses a proprietary drug-binding technology to chemically bond hyaluronic acid and diclofenac. The combination offers analgesic and anti-inflammatory effects with improved joint function.
Seikagaku and Eisai entered into an agreement to co-develop and co-market the SI-613 therapeutic agent to treat knee osteoarthritis in South Korea. This follows a similar agreement between the companies, signed earlier this year, addressing the market in China.
Seikagaku and Eisai entered into an agreement to co-develop and co-market the SI-613 therapeutic agent to treat knee osteoarthritis in South Korea. This follows a similar agreement between the companies, signed earlier this year, addressing the market in China.
Eisai Korea will acquire exclusive marketing rights for SI-613 in South Korea and apply for manufacturing and marketing approval. Following approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution. Eisai will pay Seikagaku the upfront payment and sales milestones.
SI-613 uses a proprietary drug-binding technology to chemically bond hyaluronic acid and diclofenac. The combination offers analgesic and anti-inflammatory effects with improved joint function.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
